康柏西普玻璃体腔内注射联合视网膜激光光凝对缺血型视网膜分支静脉阻塞继发黄斑水肿患者远期视力及预后影响

doi:10.3969/j.issn.1671-7171.2020.02.015

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect of intravitreal injection of Conbercept combined with retinal laser photocoagulation on the long-term vision and prognosis of patients with macular edema secondary to branch retinal vein occlusion (BRVO).【Methods】Retrospective analysis of 45 cases (45 eyes) of macular edema secondary to ischemia-type BRVO treated in our hospital from October 2016 to June 2017 was performed, all patients were treated with Conbercept vitreous injection combined with retinal laser photocoagulation; and patients' macular center retinal thickness (CMT), best corrected visual acuity (BCVA) changes were compared1 week,1 month,3 months,6 months,9 months and 12 months pre-treatment and post-treatment , and patient complications and adverse reactions were recorded .【Results】BCVA was 0.44±0.07, 0.45±0.05, 0.52±0.07, 0.54±0.06, 0.62±0.05, 0.90±0.10 at 1 week,3 months,6 months,9 months and 12 months after treatment, respectively, which was significantly higher than 0.39±0.07 before treatment. CMT was (295.14±63.51) mm,(275.39±60.14) mm,(249.63±61.50) mm,(238.75±62.55) mm,(232.64±64.71) mm,(210.08±60.09) mm, respectively, significantly lower than (679.24±62.31) mm before treatment (P<0.05). There was no significant difference in CMT at different time points after treatment (P>0.05). There were no ocular complications such as iatrogenic cataract, high intraocular pressure, retinal tear, vitreous hemorrhage and endophthalmitis.【Conclusion】Conbercept combined with retinal laser photocoagulation can significantly improve BCVA and reduce CMT in patients with macular edema secondary to BRVO, and it has high safety, which is worthy of clinical application.

Key words： Retinal vein occlusion/TH Laser coagulation Macular edema/TH

Received: 07 August 2018

PACS:

R774.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Chun-yan
	ZHANG Hai-feng
	ZHANG Xue-qin
	et al

Cite this article:

ZHAO Chun-yan,ZHANG Hai-feng,ZHANG Xue-qin, et al. Effect of Intravitreal Injection of Conbercept Combined with Retinal Laser Photocoagulation on Long-term Vision and Prognosis in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(2): 210-212.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.02.015 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I2/210

[1] 邢凯, 亢泽峰. 玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J].山东大学耳鼻喉眼学报, 2016, 30(1):80-82.
[2] Casselholmde SM, Kvanta A, Amrén U,et al. Optical coherence tomography angiography in central retinal vein occlusion: correlation between the foveal avascular zone and visual acuity[J].Invest Ophthalmol Vis Sci,2016, 57(9):242-246.
[3] 范金连, 曾琦, 段国平. 玻璃体内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的临床研究[J].医学临床研究, 2016,3(1):83-85.
[4] 邢战中, 吕杰, 李冬梅,等. 3种治疗视网膜分支静脉阻塞并发黄斑水肿方法的疗效观察[J].中国眼耳鼻喉科杂志, 2016, 16(5):333-336.
[5] 宋莉, 沙翔垠, 郑瑜,等. 康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿疗效分析[J].广东医学, 2017, 38(5):778-780.
[6] 严欢, 龚立艳, 李立. 对比康柏西普与雷珠单抗玻璃体腔注射治疗视网膜分支静脉阻塞继发黄斑水肿的疗效[J].临床眼科杂志, 2018,5(1):54-57.
[7] 陈晓凯, 李湧, 王卫平,等. 康柏西普治疗视网膜静脉阻塞继发黄斑水肿[J].中华眼外伤职业眼病杂志, 2017, 39(2):140-142.
[8] 王敏, 侯力华, 王芳,等. 康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的临床疗效[J].国际眼科杂志, 2017, 17(10):1901-1904.
[9] 刘广峰, 洪婷婷, 苗森,等. 玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究[J].眼科新进展, 2017, 37(7):658-661.
[10] 陆慧琴, 武炳慧, 吴惠琴. 玻璃体腔注射康柏西普治疗视网膜静脉阻塞并黄斑水肿[J].国际眼科杂志, 2016, 16(12):2264-2267.
[11] 周颖, 周明, 刘豪杰,等. 康柏西普治疗视网膜静脉阻塞继发黄斑水肿临床观察[J].中国实用眼科杂志, 2016, 34(6):597-600.
[12] 段雅剑, 贾亚丁, 张棉花. 玻璃体腔注射曲安奈德与联合黄斑格栅样激光光凝治疗黄斑水肿疗效的比较[J].中华眼底病杂志, 2009, 25(4):270-274.
[13] 张菁, 蔡小军, 陈晓敏,等. 玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J].中华眼底病杂志, 2015, 31(1):22-26.